

Introduction

Cancer treatment methods such as chemotherapy, radiation therapy, immunotherapy and hormone therapy have been used to treat cancers. These treatments affect cancerous as well as healthy tissues. Targeted drug delivery however can provide a focused approach to the treatment of cancers with the potential to eliminate the adverse side effects. This work follows from previous research conducted on synthesis of polymer encapsulated siRNA / iron oxide (Fe_3O_4) commercial nanoparticle complex in pilot study. The study highlighted extracellular drug release in relation to time and polymer composition of the pay loaded complex. Going forward, free standing Fe_3O_4 NPs (1 – 8 nM \varnothing) soft landed on thin film, polymer-coated 4" \varnothing silicon wafer have since been achieved. Physical vapour deposition (PVD) thin film sputtering via Mantis Nanogen Trio system was employed. Overall objective of this study is to synthesise a polymer / nanocarrier complex, pay - loaded with siRNA and with chemical properties suitable for intracellular targeted drug delivery in neuroendocrine prostate cancer (NEPC).

Methods




Fig. 1: Mantis Nanogen Trio system.




Fig. 2: PEGylated particle.

Results




Fig.3: siRNA release studies (obtained during previous phase of project).




Fig. 4: Curve evolution pre and post sputtering.




Fig. 5: Fe_3O_4 coating in centre of silicon wafer.




Fig. 6: TEM free-standing Fe_3O_4 NPs in water.

Conclusions

- PVD sputtered magnetite targets produce 1-8 nM \varnothing NPs potentially suitable size for intracellular targeted delivery.
- Water soluble polymer allows suspension of particles.
- NP dispersion may be reduced by using 2" substrate.

Further work

- Development of protocols to assess siRNA release at different pH values (using suitable fluorescent markers).
- Effect of pH on siRNA release from polymer /nano carrier complex.
- Identification and attachment of receptor specific for cancerous cell membrane biomarker for targeted delivery.
- *In vitro* and *in vivo* testing at Open University.

Dr Aver Hemben, Dr Iva Chianella and Dr Glenn Leighton.

a.hemben@cranfield.ac.uk i.chianella.1998@cranfield.ac.uk g.j.t.leighton@cranfield.ac.uk

Acknowledgements:
Thanks to the Open University for supporting this research.